Eton Pharmaceuticals, a former subsidiary of Imprimis Pharmaceuticals which is developing multiple candidates for various indications, filed on Friday with the SEC to raise up to $21 million in an initial public offering.
The Deer Park, IL-based company was founded in 2017 and plans to list on the Nasdaq under the symbol ETON. National Securities is the sole bookrunner on the deal. No pricing terms were disclosed.
